|
Drug
|
Mesh: Angiotensin-Converting Enzyme Inhibitors; Angiotensin Receptor Antagonists;
|
EMtree: dipeptidyl carboxypeptidase inhibito; angiotensin receptor antagonist;
|
|
TIAB (Title and Abstract): ACEIs; ARBs; ACEI; ARB; renin angiotensin system inhibitor*a; renin angiotensin aldosterone system inhibitor*; ACE inhibitor*; RAS inhibitor*; RAAS inhibitor*; angiotensin converting enzyme inhibitor*; renin angiotensin system inhibitor*; angiotensin receptor blocker*; Losartan; Candesartan; Valsartan; Irbesartan; Telmisartan; Eprosartan; Olmesartan; Azilsartan; Benazepril; Captopril; Enalapril; Fosinopril; Lisinopril; Moexipril; Perindopril; Quinapril; Ramipril; Trandolapril
|
ab,ti (Abstract and Title): angiotensin receptor blocker; angiotensin receptor blockers; arb; arbs; ace inhibitor; ace inhibitors; angiotensin converting enzyme inhibitor; angiotensin converting enzyme inhibitors; angiotensin converting enzyme (ace) inhibitor; angiotensin converting enzyme (ace) inhibitors; acei; aceis; renin angiotensin system inhibitor; renin angiotensin system inhibitors; renin angiotensin system (ras) inhibitor; renin angiotensin system (ras) inhibitors; ras inhibitor; ras inhibitors; renin angiotensin aldosterone system inhibitor; renin angiotensin aldosterone system inhibitors; raas inhibitor; raas inhibitors; losartan; candesartan; valsartan; irbesartan; telmisartan; eprosartan; olmesartan; azilsartan; benazepril; captopril; enalapril; fosinopril; lisinopril; moexipril; perindopril; quinapril; ramipril; trandolapril;
|
|
Diabetic Nephropathy (DN)
|
Mesh: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Kidney Failure, Chronic;
|
EMtree: non insulin dependent diabetes mellitus; diabetic nephropathy;
|
|
TIAB: diabetic nephropathy*; diabetic renal disease*; diabetic kidney disease*;
|
ab,ti: diabetic nephropathy; diabetic nephropathies; diabetic renal diseases; diabetic renal disease; diabetic kidney diseases; diabetic kidney disease
|
|
Economic Evaluation (EE)
|
Mesh: Economics, Pharmaceutical; Costs and Cost Analysis; Drug Costs; Cost Savings; Cost of Illness; Cost-Benefit Analysis;
|
EMtree: pharmacoeconomics; economic evaluation; drug cost; cost control; cost of illness; cost benefit analysis; cost effectiveness analysis;
|
|
TIAB: cost effect*; cost utility; cost benefit*; economic evaluation*; cost analys*
|
ab,ti: cost effectiveness; cost utility; cost benefit; economic evaluation; economic evaluations; cost analys;
|
|
Search Strategy
|
(“Drug Term 1”[Mesh] OR “Drug Term 2”[TIAB] …) AND (“DN Term 1”[Mesh] OR “DN Term 2”[TIAB] …) AND (“EE Term 1”[Mesh] OR “EE Term 2”[TIAB] …)
|
(‘Drug Term 1’/exp OR ‘Drug Term 2’:ab,ti …) AND (‘DN Term 1’/exp OR ‘DN Term 2’:ab,ti …) AND (‘EE Term 1’/exp OR ‘EE Term 2’:ab,ti …) NOT [medline]/lim
b
|
